Cancer immunosurveillance by ILC2s

Marek Wagner; Shigeo Koyasu

doi:10.1016/j.trecan.2022.06.010

Cancer immunosurveillance by ILC2s

Trends Cancer. 2022 Oct;8(10):792-794. doi: 10.1016/j.trecan.2022.06.010. Epub 2022 Jul 20.

Authors

Marek Wagner¹, Shigeo Koyasu²

Affiliations

¹ Laboratory for Immune Cell Systems, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Department of Biomedicine, University of Bergen, Bergen, Norway. Electronic address: marek.wagner@uib.no.
² Laboratory for Immune Cell Systems, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. Electronic address: shigeo.koyasu@riken.jp.

PMID: 35871054
DOI: 10.1016/j.trecan.2022.06.010

Abstract

Group 2 innate lymphoid cells (ILC2s) elicit ostensibly paradoxical responses, such as tissue repair and stimulation of tumorigenesis. Given emerging evidence that ILC2s also contribute to cancer immunosurveillance, we reassess the role of ILC2s in tumorigenesis and discuss recent insights into their tumoricidal potential.

Keywords: group 2 innate lymphoid cells; heterogeneity; immunity; plasticity; tumor microenvironment; tumor stroma.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinogenesis
Cell Transformation, Neoplastic
Humans
Immunity, Innate*
Lymphocytes
Monitoring, Immunologic
Neoplasms*